Published 7 days ago • loading... • Updated 7 days ago

SNS812, an innovative siRNA drug from Oneness and Microbio (Shanghai), selected for ATS 2025 oral presentation, demonstrating world-leading clinical outcomes in COVID-19 treatment

On May 16, 2025, the antiviral agent SNS812, developed collaboratively by Oneness Biotech and Microbio , was chosen for an oral presentation at the American Thoracic Society conference held in San Francisco.
SNS812 reached this milestone after a Phase II trial demonstrated potent broad-spectrum inhibition of SARS-CoV-2 via aerosol inhalation and clinical validation.
The trial revealed SNS812 significantly reduces viral load, speeds symptom resolution including shortness of breath, and shortens recovery of smell and taste without serious adverse events.
The Mini Symposium presentation will share results with over 14,000 global medical experts, confirming Oneness Biotech and Microbio's recognition in nucleic acid drug innovation.
This advancement accelerates SNS812’s commercialization, expands siRNA applications for infectious diseases, and suggests strong potential to prevent severe COVID-19 progression and offer neuroprotection.

Insights by Ground AI

Does this summary seem wrong?

14 Articles

All

Left

Center

Right

Aspen Daily News

+13 Reposted by 13 other sources

Center

SNS812, an innovative siRNA drug from Oneness and Microbio (Shanghai), selected for ATS 2025 oral presentation, demonstrating world-leading clinical outcomes in COVID-19 treatment

TAIPEI, May 16, 2025 /PRNewswire/ -- The broad-spectrum antiviral siRNA drug SNS812, co-developed by Oneness Biotech (4743.TW) and Microbio (Shanghai), has been selected for oral presentation at the prestigious 2025 American Thoracic Society (ATS) International Conference. The presentation will deliver…

7 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year